Treatment of murine corticotroph pituitary tumor cells with the BRAF inhibitor vemurafenib resulted in a greater reduction of ACTH in the cells expressing the V600E BRAF mutation compared to tumor cells with wild-type BRAF, suggesting a potential role for BRAF inhibitor therapy in patients with BRAF-mutated tumors [80]. This evidence concerns the gene BRAF and neoplasm.